FOXO4-DRI

FOXO4-DRI is a synthetic D-retro-inverso peptide derived from the FOXO4 transcription factor interaction surface with the tumor suppressor protein p53. It is classified as a protein-protein interaction interfering peptide designed to disrupt the FOXO4-p53 binding interface within senescent cells.

Through competitive disruption of nuclear FOXO4-p53 binding, FOXO4-DRI releases p53 from a survival-promoting interaction that normally maintains senescent cells in a viable, secretory state. This release permits p53-dependent apoptotic signaling to proceed selectively in senescent cells, while proliferating and quiescent cells remain largely unaffected. The D-retro-inverso configuration provides enhanced proteolytic stability while preserving the side-chain topology required for target engagement.

FOXO4-DRI is actively investigated across several research domains, including cellular-senescence biology, longevity research, chemotherapy-induced cellular-stress research models, and tissue-aging investigations. Published studies have demonstrated that FOXO4-DRI selectively induces apoptosis in senescent cells in vitro and restores fitness, fur density, and renal function parameters in naturally aged and accelerated-aging mouse models (Baar et al., 2017, Cell). Its mechanistic specificity has established FOXO4-DRI as a reference senolytic research tool.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Cellular senescence is a stable cell-cycle arrest program that limits the proliferation of damaged or stressed cells. While senescence functions as a protective mechanism, senescent cells accumulate with age and contribute to chronic inflammatory signaling, impaired tissue regeneration, and functional decline through secretion of a senescence-associated secretory phenotype (SASP).

FOXO4 is a forkhead-box transcription factor that supports the survival of senescent cells by binding to p53 within the nucleus, sequestering active p53 and preventing it from initiating apoptotic signaling. FOXO4-DRI was designed as a D-amino-acid retro-inverso peptide that mimics the FOXO4 interaction surface with p53, competitively interfering with the FOXO4-p53 complex. The retro-inverso design preserves the spatial arrangement of key side chains while increasing resistance to proteolytic degradation.

This targeted protein-protein interaction strategy distinguishes FOXO4-DRI from non-selective cytotoxic agents and positions it as a foundational research tool in senolytic biology, longevity research, and laboratory investigations of age-related tissue dysfunction.

1. Disruption of the FOXO4-p53 Interaction

FOXO4-DRI mimics the FOXO4 surface that contacts p53 and competitively occupies the binding interface. This displaces endogenous FOXO4 from nuclear p53, releasing p53 from its survival-promoting tethering interaction within senescent cells.

2. Selective Induction of p53-Dependent Apoptosis

Once released from FOXO4, active p53 can engage downstream apoptotic programs, including transcriptional activation of pro-apoptotic factors and mitochondrial outer membrane permeabilization. Because non-senescent cells do not depend on the FOXO4-p53 survival axis, apoptosis is preferentially triggered in senescent cells.

3. Reduction of Senescent Cell Burden

Through selective elimination of senescent cells, FOXO4-DRI lowers the tissue-level abundance of senescence markers such as p16^INK4a, p21, and senescence-associated beta-galactosidase activity in research models. This reduction has been associated with improved tissue homeostasis parameters in aged-mouse studies.

4. Indirect Modulation of SASP Signaling

Elimination of senescent cells decreases the source of senescence-associated secretory phenotype factors, including pro-inflammatory cytokines, chemokines, and tissue-remodeling proteases. This indirect SASP attenuation contributes to research-model observations of improved organ function following FOXO4-DRI exposure.

Research Applications

Conclusion

FOXO4-DRI is a structurally engineered D-retro-inverso peptide that selectively disrupts the FOXO4-p53 protein-protein interaction sustaining senescent cell viability. By releasing p53 to engage apoptotic signaling specifically in senescent cells, FOXO4-DRI provides a targeted research approach for studying cellular senescence, senolytic biology, and age-related tissue dysfunction. Its mechanistic specificity distinguishes it from non-selective cytotoxic strategies and supports its continued role as a reference research compound in longevity and senescence research.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.